Affiliation:
1. Department of Pharmacy, Integral University, Dasauli, Lucknow,
India
2. Department of Pharmacy, Goel Institute of Pharmaceutical Sciences,
Lucknow, India
3. Department of Bioengineering, Integral University, Dasauli, Lucknow,
India
Abstract
AbstractOvarian cancer is characterized by the establishment of tolerance, the recurrence
of disease, as well as a poor prognosis. Gene signatures in ovarian cancer cells
enable cancer medicine research, therapy, prevention, & management
problematic. Notwithstanding advances in tumor puncture surgery, novel
combinations regimens, and abdominal radiation, which can provide outstanding
reaction times, the bulk of gynecological tumor patients suffer from side
effects & relapse. As a consequence, more therapy alternatives for
individuals with ovarian cancer must always be studied to minimize side effects
and improve progression-free and total response rates. The development of cancer
medications is presently undergoing a renaissance in the quest for descriptive
and prognostic ovarian cancer biomarkers. Nevertheless, abnormalities in the
BRCA2 or BRCA1 genes, a variety of hereditary predispositions, unexplained onset
and progression, molecular tumor diversity, and illness staging can all
compromise the responsiveness and accuracy of such indicators. As a result,
current ovarian cancer treatments must be supplemented with broad-spectrum
& customized targeted therapeutic approaches. The objective of this
review is to highlight recent contributions to the knowledge of the
interrelations between selected ovarian tumor markers, various perception signs,
and biochemical and molecular signaling processes, as well as one’s
interpretation of much more targeted and effective treatment interventions.
Subject
Drug Discovery,General Medicine
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献